Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

For Roche Immuno-Oncology, It’s Steady As She Goes

Executive Summary

Roche’s oncology R&D juggernaut gains momentum with surge of combination trials around cancer immunotherapy, illustrated in an animated chart. But the company is keeping its focus on systematically building a base of randomized clinical data to back up efficacy signals for PD-L1 inhibitor Tecentriq

Advertisement

Related Content

Roche Pushes The Boundaries Of Cancer Immunotherapy
Colorectal Cancer: Isofol’s Modufolin Could Change Mainstay Therapy
4Q Pharma Results Preview, Part 2: Pfizer, Lilly, Roche, AstraZeneca, Merck, Amgen, Novo
Genentech’s Tecentriq Stakes New Claim With FDA Lung Cancer Approval
Roche Sees Cancer Combos Start To Deliver
Roche's Guide To Success In Oncology
Engineering Roche’s Next Big Thing: Bispecific Antibodies And Beyond
Early Tecentriq OK Gives Roche/Genentech Jump On PD-L1 Bladder Cancer Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC065514

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel